Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Back Drucker, DJ, Holst, JJ (28 March 2023) 'The expanding incretin universe: from basic biology to clinical translation', Diabetologia , 66, 1765-29
GLP-1RAs, such as lixisenatide, not only rely on -cell function and glucagon suppression, but also assist to lower glucose by other (insulin-independent) mechanisms such as delayed gastric emptying, underlying the clinical utility of GLP-1RAs as adjuvant therapy to basal insulin in longstanding T2DM [14]
Africa Market Insight : Increasing awareness of weight and metabolic health creates new market opportunities
Compounding can be beneficial in situations where a patient requires a specific formulation not available in standard medications, such as altering the dosage or eliminating an ingredient due to allergies
The cyclic structure can protect against enzymatic degradation while maintaining biological activity, potentially expanding the range of conditions treatable with peptide therapeutics
New England Journal of Medicine , 375 (19), 1834-1844
US$ 23.02
US$ 28.23
US$ 23.23
US$ 20.87
US$ 25.37
US$ 29.75
US$ 27.37
US$ 22.32
US$ 29.62
US$ 25.86
